Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2019-09-23 Director's Dealing
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
关于部分高级管理人员增持公司股票的公告
Director's Dealing Classification · 100% confidence The document is a public announcement from Jinling Pharmaceutical Co., Ltd. regarding certain senior management personnel increasing their holdings of company shares. It details the names, positions, methods, dates, prices, and amounts of shares purchased by these executives. The document references compliance with relevant laws and regulations concerning insider shareholding changes. There is no financial report, earnings data, or meeting materials. The content fits the definition of a Director's Dealing report, which covers personal share transactions by company directors and executives (insider trades). The document length is short (1025 characters), and it is a direct announcement of insider share purchases, not a report publication or certification. Therefore, the appropriate classification is Director's Dealing (DIRS).
2019-09-23 Chinese
关于董事长及部分高级管理人员增持公司股票的公告
Director's Dealing Classification · 100% confidence The document is a public announcement from Jinling Pharmaceutical Co., Ltd. regarding the increase in shareholdings by the chairman and several senior management personnel. It details the names, positions, methods, dates, prices, and amounts of shares purchased by these insiders. The content focuses on insider transactions of company shares by directors and executives, which aligns with the definition of Director's Dealing filings. The document is relatively short (1361 characters) and does not contain financial statements or broader financial results, so it is not an Annual Report or Earnings Release. It is not a general regulatory filing or a report publication announcement. Therefore, the classification is Director's Dealing (DIRS).
2019-09-20 Chinese
关于公司及子公司使用闲置资金购买理财产品进展的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Jinling Pharmaceutical Co., Ltd. regarding the progress of the company's and its subsidiaries' use of idle funds to purchase wealth management products. It details the amounts, dates, and types of financial products purchased and redeemed during the first half of 2019. The document includes risk disclosures and risk control measures related to these investments. It is a specific update on capital usage and investment activities rather than a full financial report or earnings release. The document length is 4234 characters, which is relatively short and focused on a specific financing activity. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2019-08-26 Chinese
第七届监事会第十四次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Jinling Pharmaceutical Co., Ltd. It details the meeting date, attendance, and resolutions passed, including approval of a change in accounting policy and the 2019 semi-annual report. The document confirms the procedures and contents of the semi-annual report but does not contain the report itself or detailed financial data. The length is short (1032 characters), and it serves as an official announcement of meeting resolutions and approvals rather than the report itself. Therefore, it fits best as a Regulatory Filing (RNS) since it is a formal disclosure of supervisory board decisions and approvals related to financial reporting, not the report itself.
2019-08-26 Chinese
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a change in accounting policies by the company Jinling Pharmaceutical Co., Ltd. It details the reasons for the change, the specific accounting standards affected, and the impact on financial statement presentation. It includes approvals from the board of directors, independent directors, and the supervisory board. The document does not contain actual financial statements or detailed financial data but rather informs stakeholders about the policy change and related board approvals. It is not a full annual or interim report, nor is it a certification or voting result. Given the nature of the content as an official announcement about accounting policy changes, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2019-08-26 Chinese
独立董事关于公司第七届董事会第十七次会议审议的有关议案及相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors of Jinling Pharmaceutical Co., Ltd. regarding the resolutions considered at the 17th meeting of the 7th Board of Directors. It discusses related party transactions, external guarantees, and accounting policy changes, and confirms compliance with laws and protection of shareholder interests. The document is not a full annual or interim report, nor an earnings release or audit report. It is a formal statement related to board meeting decisions and governance matters. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of board or senior management matters.
2019-08-26 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.